122 related articles for article (PubMed ID: 38647197)
1. Alzheimer's disease genetic risk score and neuroimaging in the FINGER lifestyle trial.
Saadmaan G; Dalmasso MC; Ramirez A; Hiltunen M; Kemppainen N; Lehtisalo J; Mangialasche F; Ngandu T; Rinne J; Soininen H; Stephen R; Kivipelto M; Solomon A
Alzheimers Dement; 2024 Jun; 20(6):4345-4350. PubMed ID: 38647197
[TBL] [Abstract][Full Text] [Related]
2. Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients.
Lehmann M; Ghosh PM; Madison C; Karydas A; Coppola G; O'Neil JP; Huang Y; Miller BL; Jagust WJ; Rabinovici GD
J Neurol Neurosurg Psychiatry; 2014 Mar; 85(3):266-73. PubMed ID: 23965289
[TBL] [Abstract][Full Text] [Related]
3. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
4. Synergistic interaction between APOE and family history of Alzheimer's disease on cerebral amyloid deposition and glucose metabolism.
Yi D; Lee Y; Byun MS; Lee JH; Ko K; Sohn BK; Choe YM; Choi HJ; Baek H; Sohn CH; Kim YK; Lee DY;
Alzheimers Res Ther; 2018 Aug; 10(1):84. PubMed ID: 30134963
[TBL] [Abstract][Full Text] [Related]
5. Interaction Between BDNF Val66Met and APOE4 on Biomarkers of Alzheimer's Disease and Cognitive Decline.
Stonnington CM; Velgos SN; Chen Y; Syed S; Huentelman M; Thiyyagura P; Lee W; Richholt R; Caselli RJ; Locke DEC; Lu B; Reiman EM; Su Y; Chen K
J Alzheimers Dis; 2020; 78(2):721-734. PubMed ID: 33044176
[TBL] [Abstract][Full Text] [Related]
6. Change in CAIDE Dementia Risk Score and Neuroimaging Biomarkers During a 2-Year Multidomain Lifestyle Randomized Controlled Trial: Results of a Post-Hoc Subgroup Analysis.
Stephen R; Ngandu T; Liu Y; Peltonen M; Antikainen R; Kemppainen N; Laatikainen T; Lötjönen J; Rinne J; Strandberg T; Tuomilehto J; Vanninen R; Soininen H; Kivipelto M; Solomon A;
J Gerontol A Biol Sci Med Sci; 2021 Jul; 76(8):1407-1414. PubMed ID: 33970268
[TBL] [Abstract][Full Text] [Related]
7. Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.
Chételat G; Fouquet M
Rev Neurol (Paris); 2013 Oct; 169(10):729-36. PubMed ID: 24016463
[TBL] [Abstract][Full Text] [Related]
8. ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels.
Steward A; Biel D; Dewenter A; Roemer S; Wagner F; Dehsarvi A; Rathore S; Otero Svaldi D; Higgins I; Brendel M; Dichgans M; Shcherbinin S; Ewers M; Franzmeier N
JAMA Neurol; 2023 Dec; 80(12):1295-1306. PubMed ID: 37930695
[TBL] [Abstract][Full Text] [Related]
9. Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4.
Belloy ME; Napolioni V; Han SS; Le Guen Y; Greicius MD;
JAMA Neurol; 2020 Jul; 77(7):849-862. PubMed ID: 32282020
[TBL] [Abstract][Full Text] [Related]
10. Associations of lifestyle and vascular risk factors with Alzheimer's brain biomarker changes during middle age: a 3-year longitudinal study in the broader New York City area.
Walters MJ; Sterling J; Quinn C; Ganzer C; Osorio RS; Andrews RD; Matthews DC; Vallabhajosula S; de Leon MJ; Isaacson RS; Mosconi L
BMJ Open; 2018 Nov; 8(11):e023664. PubMed ID: 30478117
[TBL] [Abstract][Full Text] [Related]
11. Regional patterns of gray matter volume, hypometabolism, and beta-amyloid in groups at risk of Alzheimer's disease.
Wirth M; Bejanin A; La Joie R; Arenaza-Urquijo EM; Gonneaud J; Landeau B; Perrotin A; Mézenge F; de La Sayette V; Desgranges B; Chételat G
Neurobiol Aging; 2018 Mar; 63():140-151. PubMed ID: 29203090
[TBL] [Abstract][Full Text] [Related]
12. APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls.
Sampedro F; Vilaplana E; de Leon MJ; Alcolea D; Pegueroles J; Montal V; Carmona-Iragui M; Sala I; Sánchez-Saudinos MB; Antón-Aguirre S; Morenas-Rodríguez E; Camacho V; Falcón C; Pavía J; Ros D; Clarimón J; Blesa R; Lleó A; Fortea J;
Oncotarget; 2015 Sep; 6(29):26663-74. PubMed ID: 26397226
[TBL] [Abstract][Full Text] [Related]
13. Nutrient intake and brain biomarkers of Alzheimer's disease in at-risk cognitively normal individuals: a cross-sectional neuroimaging pilot study.
Mosconi L; Murray J; Davies M; Williams S; Pirraglia E; Spector N; Tsui WH; Li Y; Butler T; Osorio RS; Glodzik L; Vallabhajosula S; McHugh P; Marmar CR; de Leon MJ
BMJ Open; 2014 Jun; 4(6):e004850. PubMed ID: 24961717
[TBL] [Abstract][Full Text] [Related]
14. Serum Thioredoxin-80 is associated with age, ApoE4, and neuropathological biomarkers in Alzheimer's disease: a potential early sign of AD.
Goikolea J; Gerenu G; Daniilidou M; Mangialasche F; Mecocci P; Ngandu T; Rinne J; Solomon A; Kivipelto M; Cedazo-Minguez A; Sandebring-Matton A; Maioli S
Alzheimers Res Ther; 2022 Feb; 14(1):37. PubMed ID: 35209952
[TBL] [Abstract][Full Text] [Related]
15. Association of
Xicota L; Gyorgy B; Grenier-Boley B; Lecoeur A; Fontaine G; Danjou F; Gonzalez JS; Colliot O; Amouyel P; Martin G; Levy M; Villain N; Habert MO; Dubois B; Lambert JC; Potier MC;
Neurology; 2022 Aug; 99(5):e462-e475. PubMed ID: 35606148
[TBL] [Abstract][Full Text] [Related]
16. Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy.
Whitwell JL; Ahlskog JE; Tosakulwong N; Senjem ML; Spychalla AJ; Petersen RC; Jack CR; Lowe VJ; Josephs KA
Parkinsonism Relat Disord; 2018 Mar; 48():3-9. PubMed ID: 29254665
[TBL] [Abstract][Full Text] [Related]
17. Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan.
Fouquet M; Besson FL; Gonneaud J; La Joie R; Chételat G
Neuropsychol Rev; 2014 Sep; 24(3):290-9. PubMed ID: 25146994
[TBL] [Abstract][Full Text] [Related]
18. Atypical Localization and Dissociation between Glucose Uptake and Amyloid Deposition in Cognitively Normal APOE*E4 Homozygotic Elders Compared with Patients with Late-Onset Alzheimer's Disease.
Pardo JV; Lee JT;
eNeuro; 2018; 5(1):. PubMed ID: 29497704
[TBL] [Abstract][Full Text] [Related]
19. Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network.
Bussy A; Snider BJ; Coble D; Xiong C; Fagan AM; Cruchaga C; Benzinger TLS; Gordon BA; Hassenstab J; Bateman RJ; Morris JC;
Neurobiol Aging; 2019 Mar; 75():42-50. PubMed ID: 30530186
[TBL] [Abstract][Full Text] [Related]
20. Increased Alzheimer's risk during the menopause transition: A 3-year longitudinal brain imaging study.
Mosconi L; Rahman A; Diaz I; Wu X; Scheyer O; Hristov HW; Vallabhajosula S; Isaacson RS; de Leon MJ; Brinton RD
PLoS One; 2018; 13(12):e0207885. PubMed ID: 30540774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
